Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
BÂRRX Medical, Inc. |
---|---|
Information provided by: | BÂRRX Medical, Inc. |
ClinicalTrials.gov Identifier: | NCT00848237 |
The HALO Patient Registry is a prospective/retrospective, multi-center patient registry. It provides a framework for treatment and follow-up of patients with Barrett's esophagus (non-dysplastic IM, LGD and HGD). The primary objective is to provide a tool for participating physician investigators to collect outcomes data related to the use of the HALO Ablation Systems.
Condition | Intervention |
---|---|
Barrett Esophagus |
Device: Radiofrequency Ablation (HALO Ablation Systems) |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | HALO Patient Registry: Ablation of Barrett's Esophagus, A Multi-Center Patient Registry |
Estimated Enrollment: | 3000 |
Study Start Date: | July 2007 |
Estimated Study Completion Date: | December 2010 |
Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Treatment: Experimental
All Patients with Barrett's esophagus or Intestinal metaplasia which is visible endoscopically or histologically may be treated with the Radiofrequency ablation system.
|
Device: Radiofrequency Ablation (HALO Ablation Systems)
Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.
|
Summary The HALO Patient Registry provides a framework for treatment and follow-up of patients with Barrett's esophagus (non-dysplastic IM, LGD and HGD). The primary objective is to provide a tool for participating physician investigators to collect outcomes data related to the use of the HALO Ablation Systems.
Protocol Design:
This is a prospective, multi-center patient Registry. Sites may choose to also retrospectively enroll previously treated patients (after obtaining informed consent) and enter retrospective data into case report forms on-line.
"Retrospective data collection" is defined as any data other than patient history collected prior to signing of the informed consent. A set of case report forms (CRFs) is provided along with this protocol to track outcomes. The CRFs may be completed and retained on site, but the site is recommended to utilize the internet-based data entry system.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Shirin R Hasan | 408-328-7338 | shasan@barrx.com |
Contact: David S Utley, MD | 408-328-7309 | dutley@barrx.com |
United States, Tennessee | |
Gastrointestinal Associates | Recruiting |
Knoxville, Tennessee, United States, 37909 |
Study Director: | David S Utley, MD | BÂRRX Medical, Inc. |
Responsible Party: | Barrx Medical Inc ( David S. Utley, MD ) |
Study ID Numbers: | B-500 |
Study First Received: | December 20, 2007 |
Last Updated: | March 16, 2009 |
ClinicalTrials.gov Identifier: | NCT00848237 History of Changes |
Health Authority: | United States: Institutional Review Board |
Barrett's Esophagus Dysplasia Intestinal Metaplasia |
Digestive System Diseases Digestive System Abnormalities Proton Pump Inhibitors Esophageal Disorder Barrett Syndrome |
Gastrointestinal Diseases Metaplasia Barrett Esophagus Esophageal Diseases Congenital Abnormalities |
Digestive System Diseases Digestive System Abnormalities Gastrointestinal Diseases Barrett Esophagus Esophageal Diseases |